A FIRST-IN-HUMAN (FIH) STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES, AND ALTERNATIVE FORMULATIONS OF R941552 (R552), A SELECTIVE RECEPTOR INTERACTING PROTEIN 1 (RIP1) KINASE INHIBITOR.

被引：0
|
作者：
Yan, L. [1 ]
Park, G. [1 ]
Chow, D. [1 ]
Shaw, S. [1 ]
Blasingame, D. [1 ]
Singh, N. [2 ]
Zann, V. [3 ]
Chow, A. [1 ]
机构：
[1] Rigel Pharmaceut, San Francisco, CA USA
[2] Quotient Sci, Nottingham, England
[3] Quotient Sci, Herston, Qld, Australia
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-042
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 11 条
  • [1] Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects
    Nelson, Cara H.
    Etchevers, Kim
    Yi, Saili
    Breckenridge, David
    Hepner, Mischa
    Patel, Uptal
    Ling, John
    Mathias, Anita
    CLINICAL PHARMACOKINETICS, 2020, 59 (09) : 1109 - 1117
  • [2] Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects
    Cara H. Nelson
    Kim Etchevers
    Saili Yi
    David Breckenridge
    Mischa Hepner
    Uptal Patel
    John Ling
    Anita Mathias
    Clinical Pharmacokinetics, 2020, 59 : 1109 - 1117
  • [3] SYNERGY-1: A Phase 1, First-in-Human, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics Study of KP104 in Escalating Single and Multiple Doses
    Wabnitz, Paul
    Gao, Xiang
    Ma, Jay
    Tsui, Ping
    Rabe, Martin
    Fu, Helen N.
    He, Chaomei
    Wu, Jingtao
    York, Brian K.
    Weng, Christina
    Rankin, Jon
    Beddingfield, Frederick C.
    Song, Wenru
    Farinola, Nicholas
    Lee, Richard
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 779 - 779
  • [4] First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection
    Bergougnan, Luc
    Armani, Sara
    Golor, Georg
    Tardat, Agnes
    Vitse, Olivier
    Hurbin, Fabrice
    Scemama, Michel
    Poitiers, Franck
    Radzik, David
    Gaudin, Christophe
    Hovsepian, Lionel
    Muslin, Anthony J.
    Kirkesseli, Stephane
    Deutsch, Paul
    Parkar, Ashfaq A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 598 - 611
  • [5] BMS-754807, an oral dual IGF-1R/IR inhibitor: First-in-human single-dose study of safety, tolerability, pharmacokinetics, and pharmacodynacmics in healthy subjects
    Clemens, Pamela L.
    Park, Jong-Soon
    Cohen, Marvin B.
    Zhang, Duxi
    Huang, Fei
    Hodsman, Peter
    Finckenstein, Friedrich Graf
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants
    Feng, Sheng
    Gane, Edward
    Schwabe, Christian
    Zhu, Mingfen
    Triyatni, Miriam
    Zhou, Julian
    Bo, Qingyan
    Jin, Yuyan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [7] Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese SubjectsAn Open-Label, Single-Center, First-in-Human Study
    Luning Sun
    Li Ding
    Yongqing Wang
    Wenjia Zhou
    Zhengyu Yan
    Weilin Sun
    Hongwen Zhang
    Ning Ou
    Xiaoping Chen
    Drugs in R&D, 2012, 12 (1) : 17 - 28
  • [8] Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese Subjects An Open-Label, Single-Center, First-in-Human Study
    Sun, Luning
    Ding, Li
    Wang, Yongqing
    Zhou, Wenjia
    Yan, Zhengyu
    Sun, Weilin
    Zhang, Hongwen
    Ou, Ning
    Chen, Xiaoping
    DRUGS IN R&D, 2012, 12 (01) : 17 - 28
  • [9] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    DIABETES, 2022, 71
  • [10] Phase 1 study of C019199, an oral CSF-1R/DDRs/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including tenosynovial giant cell tumor
    Shen, Lin
    Ye, Feng
    Gong, Jifang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12